Last Updated: September 26, 2026

Patent: 10,233,256

✉ Email this page to a colleague

Summary for Patent: 10,233,256

Title:	Antibodies directed to ricin toxin
Abstract:	An isolated monoclonal antibody or any antigen-binding fragment thereof which binds to ricin toxin, an expression vector including the isolated nucleic acid molecule and a host cell transfected with said isolated nucleic acid molecule or with the expression vector, a pharmaceutical composition including as an active ingredient the isolated monoclonal antibody or any antigen-binding fragment thereof, the bispecific molecule or the immunoconjugate and a pharmaceutically acceptable carrier, excipient or diluent, and a method of prophylaxis, treatment or amelioration of ricin toxin poisoning including administering to a subject in need thereof a therapeutically effective amount of the isolated monoclonal antibody or any antigen-binding fragment thereof, the bispecific molecule, the immunoconjugate or the pharmaceutical composition.
Inventor(s):	Ohad Mazor, Ronit Rosenfeld, Arie ORDENTLICH, Tal NOY-PORAT
Assignee:	Israel Institute Of Biological Research (iibr)
Application Number:	US14/952,283
Patent Claims:	see list of patent claims

Details for Patent 10,233,256

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	TREMFYA	guselkumab	Injection	761061	13-Jul-17	⤷ Start Trial	2035-11-25
Janssen Biotech, Inc.	TREMFYA	guselkumab	Injection	761061	28-Jan-19	⤷ Start Trial	2035-11-25
Janssen Biotech, Inc.	TREMFYA	guselkumab	Injection	761061	11-Sep-24	⤷ Start Trial	2035-11-25
Janssen Biotech, Inc.	TREMFYA	guselkumab	Injection	761061	25-Mar-25	⤷ Start Trial	2035-11-25
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 10,233,256

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Israel	242791	⤷ Start Trial
United States of America	10208108	⤷ Start Trial
United States of America	2016152732	⤷ Start Trial
United States of America	2017174752	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.